The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Ketoprofen and omeprazole (Axorid®) has been rejected for the symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a previous history or who are at risk of developing NSAID associated ulcers or erosions in whom continued treatment with ketoprofen is essential. The economic analysis provided was not sufficiently robust to gain approval.
Saxagliptin (Onglyza®) has been accepted for restricted use in adult patients with type 2 diabetes mellitus as add-on combination therapy with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control. This agent is only recommended when the addition of sulphonylureas is not appropriate and is an alternative to other agents such as thiazolidinediones (glitazones).
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Aspirin ineffective in those with low ABI||Drug Safety Update - March 2010 »|